The Drug Enforcement Administration and Substance Abuse and Mental Health Services Administration Oct. 6 released a temporary rule extending telehealth prescribing flexibilities for buprenorphine and other controlled substances for new practitioner-patient relationships through Dec. 31, 2024. The agencies previously extended the flexibilities through Nov. 11, 2024, while they consider changes to proposed rules released in March that would limit telehealth prescriptions for buprenorphine and other controlled substances to a 30-day supply unless the prescriber or referring clinician have evaluated the patient in person. 
 
AHA has urged the agencies to establish a special registration process (as statutorily mandated) to waive the in-person evaluations for practitioners who register with the DEA.

Related News Articles

Blog
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient outcomes.1 Nearly 30% of…
Headline
The House Energy and Commerce Subcommittee on Health May 16 passed a number of bills during a markup session, including AHA-supported legislation. The…
Headline
AHA submitted a statement May 8 to the House Ways and Means Committee for a markup session on proposed legislation impacting telehealth access for patients and…
Headline
In a letter submitted May 7 to a bipartisan group of senators, AHA urged Congress to extend the Affordable Connectivity Program, which provides benefits toward…
Headline
Sen. John Thune, R-S.D., April 16 updated AHA members on progress to extend telehealth waivers, offering hope that a solution will arise in end-of-year…
Headline
Rep. Morgan Griffith, R-Va., touted the benefits of telehealth April 15, saying it is uncovering hidden health care savings by encouraging patients to seek…